Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients

Shunji Takahashi, Keisuke Aiba, Yoshinori Ito, Kiyohiko Hatake, Minoru Nakane, Takayuki Kobayashi, Sayuri Minowa, Harumi Shibata, Junko Mitsuhashi, Satomi Tsukahara, Etsuko Ishikawa, Rieko Suzuki, Takashi Tsuruo, Yoshikazu Sugimoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A major problem in high-dose chemotherapy with autologous hematopoietic stem cell transplantation is insufficient function of reconstituted bone marrow that limits the efficacy of post-transplantation chemotherapy. Because transduction of hematopoietic stem cells with the multidrug resistance 1 (MDR1) gene might circumvent this problem, we conducted a pilot study of MDR1 gene therapy against metastatic breast cancer. Peripheral blood stem cells were harvested, and one-third of the cells were transduced with MDR1 retrovirus. After the reconstitution of bone marrow function, the patients received high-dose chemotherapy with transplantation of both MDR1-transduced and unprocessed peripheral blood stem cells. The patients then received docetaxel chemotherapy. Two patients received transplantation of the MDR1-transduced cells in 2001. Peripheral blood MDR1-transduced leukocytes were 3-5% of the total cells after transplantation, but decreased gradually. During docetaxel chemotherapy, an increase in the rate of MDR1-transduced leukocytes (up to 10%) was observed. Comparison of docetaxel-induced granulocytopenia in the two patients suggested a bone marrow-protective effect of the MDR1-transduced cells. No serious side-effect was observed, and the patients were in complete remission for more than 3 years. The MDR1-transduced cells gradually decreased and disappeared almost entirely by the end of 2004. Results of linear amplification-mediated polymerase chain reaction of the MDR1-transduced leukocytes suggested no sign of abnormal amplification of the transduced cells. A third patient received transplantation of the MDR1 -transduced cells in 2004. These results suggest the feasibility of our MDR1 gene therapy against metastatic breast cancer, and follow-up is ongoing.

Original languageEnglish
Pages (from-to)1609-1616
Number of pages8
JournalCancer Science
Volume98
Issue number10
DOIs
Publication statusPublished - 2007 Oct

Fingerprint

MDR Genes
Multiple Drug Resistance
Hematopoietic Stem Cells
docetaxel
Breast Neoplasms
Drug Therapy
Transplantation
Leukocytes
Bone Marrow
Genetic Therapy
Agranulocytosis
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Retroviridae
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. / Takahashi, Shunji; Aiba, Keisuke; Ito, Yoshinori; Hatake, Kiyohiko; Nakane, Minoru; Kobayashi, Takayuki; Minowa, Sayuri; Shibata, Harumi; Mitsuhashi, Junko; Tsukahara, Satomi; Ishikawa, Etsuko; Suzuki, Rieko; Tsuruo, Takashi; Sugimoto, Yoshikazu.

In: Cancer Science, Vol. 98, No. 10, 10.2007, p. 1609-1616.

Research output: Contribution to journalArticle

Takahashi, S, Aiba, K, Ito, Y, Hatake, K, Nakane, M, Kobayashi, T, Minowa, S, Shibata, H, Mitsuhashi, J, Tsukahara, S, Ishikawa, E, Suzuki, R, Tsuruo, T & Sugimoto, Y 2007, 'Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients', Cancer Science, vol. 98, no. 10, pp. 1609-1616. https://doi.org/10.1111/j.1349-7006.2007.00571.x
Takahashi, Shunji ; Aiba, Keisuke ; Ito, Yoshinori ; Hatake, Kiyohiko ; Nakane, Minoru ; Kobayashi, Takayuki ; Minowa, Sayuri ; Shibata, Harumi ; Mitsuhashi, Junko ; Tsukahara, Satomi ; Ishikawa, Etsuko ; Suzuki, Rieko ; Tsuruo, Takashi ; Sugimoto, Yoshikazu. / Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. In: Cancer Science. 2007 ; Vol. 98, No. 10. pp. 1609-1616.
@article{e0b0d1d1f259453da9dfb57f37304c6f,
title = "Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients",
abstract = "A major problem in high-dose chemotherapy with autologous hematopoietic stem cell transplantation is insufficient function of reconstituted bone marrow that limits the efficacy of post-transplantation chemotherapy. Because transduction of hematopoietic stem cells with the multidrug resistance 1 (MDR1) gene might circumvent this problem, we conducted a pilot study of MDR1 gene therapy against metastatic breast cancer. Peripheral blood stem cells were harvested, and one-third of the cells were transduced with MDR1 retrovirus. After the reconstitution of bone marrow function, the patients received high-dose chemotherapy with transplantation of both MDR1-transduced and unprocessed peripheral blood stem cells. The patients then received docetaxel chemotherapy. Two patients received transplantation of the MDR1-transduced cells in 2001. Peripheral blood MDR1-transduced leukocytes were 3-5{\%} of the total cells after transplantation, but decreased gradually. During docetaxel chemotherapy, an increase in the rate of MDR1-transduced leukocytes (up to 10{\%}) was observed. Comparison of docetaxel-induced granulocytopenia in the two patients suggested a bone marrow-protective effect of the MDR1-transduced cells. No serious side-effect was observed, and the patients were in complete remission for more than 3 years. The MDR1-transduced cells gradually decreased and disappeared almost entirely by the end of 2004. Results of linear amplification-mediated polymerase chain reaction of the MDR1-transduced leukocytes suggested no sign of abnormal amplification of the transduced cells. A third patient received transplantation of the MDR1 -transduced cells in 2004. These results suggest the feasibility of our MDR1 gene therapy against metastatic breast cancer, and follow-up is ongoing.",
author = "Shunji Takahashi and Keisuke Aiba and Yoshinori Ito and Kiyohiko Hatake and Minoru Nakane and Takayuki Kobayashi and Sayuri Minowa and Harumi Shibata and Junko Mitsuhashi and Satomi Tsukahara and Etsuko Ishikawa and Rieko Suzuki and Takashi Tsuruo and Yoshikazu Sugimoto",
year = "2007",
month = "10",
doi = "10.1111/j.1349-7006.2007.00571.x",
language = "English",
volume = "98",
pages = "1609--1616",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients

AU - Takahashi, Shunji

AU - Aiba, Keisuke

AU - Ito, Yoshinori

AU - Hatake, Kiyohiko

AU - Nakane, Minoru

AU - Kobayashi, Takayuki

AU - Minowa, Sayuri

AU - Shibata, Harumi

AU - Mitsuhashi, Junko

AU - Tsukahara, Satomi

AU - Ishikawa, Etsuko

AU - Suzuki, Rieko

AU - Tsuruo, Takashi

AU - Sugimoto, Yoshikazu

PY - 2007/10

Y1 - 2007/10

N2 - A major problem in high-dose chemotherapy with autologous hematopoietic stem cell transplantation is insufficient function of reconstituted bone marrow that limits the efficacy of post-transplantation chemotherapy. Because transduction of hematopoietic stem cells with the multidrug resistance 1 (MDR1) gene might circumvent this problem, we conducted a pilot study of MDR1 gene therapy against metastatic breast cancer. Peripheral blood stem cells were harvested, and one-third of the cells were transduced with MDR1 retrovirus. After the reconstitution of bone marrow function, the patients received high-dose chemotherapy with transplantation of both MDR1-transduced and unprocessed peripheral blood stem cells. The patients then received docetaxel chemotherapy. Two patients received transplantation of the MDR1-transduced cells in 2001. Peripheral blood MDR1-transduced leukocytes were 3-5% of the total cells after transplantation, but decreased gradually. During docetaxel chemotherapy, an increase in the rate of MDR1-transduced leukocytes (up to 10%) was observed. Comparison of docetaxel-induced granulocytopenia in the two patients suggested a bone marrow-protective effect of the MDR1-transduced cells. No serious side-effect was observed, and the patients were in complete remission for more than 3 years. The MDR1-transduced cells gradually decreased and disappeared almost entirely by the end of 2004. Results of linear amplification-mediated polymerase chain reaction of the MDR1-transduced leukocytes suggested no sign of abnormal amplification of the transduced cells. A third patient received transplantation of the MDR1 -transduced cells in 2004. These results suggest the feasibility of our MDR1 gene therapy against metastatic breast cancer, and follow-up is ongoing.

AB - A major problem in high-dose chemotherapy with autologous hematopoietic stem cell transplantation is insufficient function of reconstituted bone marrow that limits the efficacy of post-transplantation chemotherapy. Because transduction of hematopoietic stem cells with the multidrug resistance 1 (MDR1) gene might circumvent this problem, we conducted a pilot study of MDR1 gene therapy against metastatic breast cancer. Peripheral blood stem cells were harvested, and one-third of the cells were transduced with MDR1 retrovirus. After the reconstitution of bone marrow function, the patients received high-dose chemotherapy with transplantation of both MDR1-transduced and unprocessed peripheral blood stem cells. The patients then received docetaxel chemotherapy. Two patients received transplantation of the MDR1-transduced cells in 2001. Peripheral blood MDR1-transduced leukocytes were 3-5% of the total cells after transplantation, but decreased gradually. During docetaxel chemotherapy, an increase in the rate of MDR1-transduced leukocytes (up to 10%) was observed. Comparison of docetaxel-induced granulocytopenia in the two patients suggested a bone marrow-protective effect of the MDR1-transduced cells. No serious side-effect was observed, and the patients were in complete remission for more than 3 years. The MDR1-transduced cells gradually decreased and disappeared almost entirely by the end of 2004. Results of linear amplification-mediated polymerase chain reaction of the MDR1-transduced leukocytes suggested no sign of abnormal amplification of the transduced cells. A third patient received transplantation of the MDR1 -transduced cells in 2004. These results suggest the feasibility of our MDR1 gene therapy against metastatic breast cancer, and follow-up is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=34548159791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548159791&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00571.x

DO - 10.1111/j.1349-7006.2007.00571.x

M3 - Article

C2 - 17683514

AN - SCOPUS:34548159791

VL - 98

SP - 1609

EP - 1616

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -